Gebhard Thoma

This inventor holds 18 USPTO granted patents and 9 published patent applications, plus 2 CIPO patents and 5 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Novartis Ag, Astex Therapeutics Limited. Active years: 2002-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gebhard Thoma. Retrieved from https://idiyas.com/inventor/gebhard-thoma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 18 (Patent Applications = 9)

% Patents Active = 55.6

CIPO Patents = 2

EPO Patents = 5 (Patent Applications = 2)

Average Co-Inventor Count = 3.9

ph-index = 7

Forward Citations = 168(Granted Patents)

Location History:

Basel, CH (2012)
Lorrach, DE (2016 - 2022)
Lörrach, DE (2002 - 2024)

Company Filing History:

Astex Therapeutics Limited

patents

Years Active: 2002-2024

Loading Chart...

Areas of Expertise:

Heteroaryl Derivatives

Pyrimidine Compounds

Spiropiperidinyl

Diamino Pyridine

Bicyclic Compounds

Monocyclic Compounds

ZAP-70 Inhibitors

CXCR4 Inhibitors

Piperidine Derivatives

Neoglycoproteins

Multivalent Polymers

Pharmaceutical Uses

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12157737 - Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof (2024-12-03),

2. 11932630 - Heteroaryl aminopropanol derivatives (2024-03-19),

3. 11708366 - Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof (2023-07-25),

4. 11274080 - Diamino pyridine derivatives (2022-03-15),

5. 10570096 - Diamino pyridine derivatives (2020-02-25),

6. 9315500 - Bicyclic heteroaryl cycloalkyldiamine derivatives (2016-04-19),

7. 9290481 - Monocyclic heteroaryl cycloalkyldiamine derivatives (2016-03-22),

8. 8431589 - 2,4-diaminopyrimidine derivatives (2013-04-30),

9. 8324225 - Pyrrolopyrimidine compounds and their uses (2012-12-04),

10. 8283356 - 2,4- Di(hetero)-arylamino-pyrimidine derivatives as ZAP-70 and/or SYK inhibitors (2012-10-09),

11. 7943627 - 2,4-diaminopyrimidine derivatives (2011-05-17),

12. 7671078 - Isothiourea derivatives of imadazo[2,1-b]Thiazoles and 5,6-dihydro derivatives thereof useful as CXCR4 chemokine receptor inhibitors (2010-03-02),

13. 7671063 - 2,4 Di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or syk inhibitors (2010-03-02),

14. 7666877 - Ergoline derivatives (2010-02-23),

15. 7399771 - Piperidine derivatives as CCR5 inhibitors (2008-07-15),

Title: Gebhard Thoma: Innovator in Pharmaceutical Chemistry

Introduction

Gebhard Thoma is a distinguished inventor based in Lörrach, Germany. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 18 patents. His work focuses on developing innovative compounds with therapeutic applications.

Latest Patents

Among his latest patents are "Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof," which provides a compound of formula (I) or a pharmaceutically acceptable salt thereof. Another notable patent is "Heteroaryl aminopropanol derivatives," which includes a method for manufacturing the compounds and their therapeutic uses. This invention also offers a combination of pharmacologically active agents and a pharmaceutical composition.

Career Highlights

Throughout his career, Gebhard Thoma has worked with prominent companies in the pharmaceutical industry, including Novartis AG and Astex Therapeutics Limited. His expertise in drug development has led to advancements in various therapeutic areas.

Collaborations

He has collaborated with notable professionals in the field, including Rudolf Duthaler and Rolf Baenteli. These partnerships have contributed to the success of his innovative projects.

Conclusion

Gebhard Thoma's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as a key innovator in the industry. His work continues to impact the development of new therapeutic agents.

Profile summary based on public USPTO records.